.webp)
PHARMACEUTICAL ETP CASE STUDY
How a 30 KLD Pharma ETP Achieved 90% COD Reduction in 25 Days
Industry: Oral Cephalosporin APIs (Cefixime, Cefdinir, Cefaclor, Cefuroxime Axetil, Cefpodoxime Proxetil, Cefditoren Pivoxil, Cefprozil)
Plant Capacity: 30 KLD ETP | Core Tech: UASBR
85–90%
COD Reduction (7,187 → 874 mg/L)
0.18
Optimal VFA/Alkalinity Ratio
25 Days
Full System Commissioning
This pharmaceutical wastewater treatment case study explains how a 30 KLD Oral Cephalosporin API manufacturing plant commissioned its Up-flow Anaerobic Sludge Blanket Reactor (UASBR) in just 25 days using BactaServe Anaerobic. The project achieved 85 to 90% COD reduction, maintained a stable VFA to alkalinity ratio of 0.18, and established healthy granular sludge formation without using conventional seed sludge.
1. Background & Technical Challenge
Plant Overview
A leading Indian pharmaceutical company specialising in the manufacture and export of high-purity Oral Cephalosporin Active Pharmaceutical Ingredients (APIs) operates a 30 KLD Effluent Treatment Plant (ETP) designed to treat high-strength industrial wastewater generated during API production.
The treatment facility uses a combination of anaerobic and aerobic biological processes, with the Up-flow Anaerobic Sludge Blanket Reactor (UASBR) serving as the primary treatment unit for removing high organic loads before secondary biological treatment and tertiary polishing.
During commissioning, the plant required rapid biological stabilisation to achieve consistent treatment efficiency while meeting environmental discharge standards and avoiding production delays. The primary objective was to establish a healthy anaerobic microbial population capable of efficiently degrading complex pharmaceutical organics without the lengthy start-up period associated with conventional seed sludge.
The Technical Challenge & Risk
High Organic Loading: Influent COD levels of 7,000 to 8,000 mg/L created a high organic load that delayed stable anaerobic digestion.
Slow Biological Commissioning: Traditional seed sludge typically requires 60 to 90 days to establish an active microbial population.
VFA Accumulation: Rapid acid formation during start-up increased the risk of reactor souring and unstable biological performance.
Poor Granular Sludge Formation: Insufficient microbial granulation reduced biomass retention and affected long-term reactor stability.
Regulatory Compliance Pressure: The plant needed rapid biological stabilisation to consistently meet environmental discharge standards.
2. Treatment Process Flow Diagram
The integrated treatment process routes raw effluent through biological and tertiary filtration units:
Process units mapped based on actual plant flow: Raw Effluent → Collection Tank → Equalization Tank → Buffer Tank → UASBR → Primary Settling Tank → Aeration Tank → Secondary Settling Tank → ACF/PSF → UF → Outlet
Process Overview
Collection & Equalisation: Balances wastewater flow, pH, and pollutant concentration for stable treatment.
Buffer Tank: Regulates hydraulic loading and provides consistent feed to the UASBR.
UASBR: Anaerobic bacteria break down complex organic matter through hydrolysis, acidogenesis, acetogenesis, and methanogenesis, achieving the majority of COD removal.
Secondary Biological Treatment: Aeration tank and secondary clarifier remove remaining biodegradable organic matter and suspended solids.
Tertiary Polishing: ACF, PSF, and UF systems eliminate fine solids, colour, and residual impurities for compliant discharge or reuse.
3. Specialised Solution: BactaServe Anaerobic
Why BactaServe Anaerobic Was Selected
To accelerate UASBR commissioning, Amalgam Biotech implemented BactaServe Anaerobic, a specialised microbial consortium developed for high-strength industrial wastewater. Unlike conventional seed sludge, it rapidly establishes active anaerobic biomass, accelerates the breakdown of complex pharmaceutical organics, and supports all four stages of anaerobic digestion, enabling faster and more stable reactor start-up.
Key Benefits
Rapid establishment of anaerobic biomass
Faster degradation of complex pharmaceutical organics
Controlled VFA accumulation during commissioning
Enhanced methane production and granular sludge formation
Improved resistance to shock organic loading
Reduced commissioning time with stable long-term UASBR performance
How BactaServe Anaerobic Works
BactaServe Anaerobic contains a specialised consortium of anaerobic microorganisms that accelerate biological degradation inside the UASBR. The microbes work together through four sequential stages, converting complex pharmaceutical organics into methane-rich biogas while maintaining reactor stability.
1. Hydrolysis
Breaks API polymers into soluble monomers.
2. Acidogenesis
Converts monomers into VFAs and alcohols.
3. Acetogenesis
Transforms VFAs into acetic acid, CO₂, and H₂.
4. Methanogenesis
Converts acetic acid & H₂ into biogas (CH₄ & CO₂).
BactaServe Anaerobic Dosing Protocol (30 KLD Capacity)
A gradual dosing strategy allowed the microbial population to establish, adapt, and multiply without creating biological shock inside the reactor.
Day Sequence | Daily Dosage (kg/day) | Cumulative Total (kg) |
Day 1 | 5 kg | 5 kg |
Day 5 | 5 kg | 10 kg |
Day 10 | 5 kg | 15 kg |
Day 15 | 5 kg | 20 kg |
Day 20 | 5 kg | 25 kg |
Day 25 | 5 kg | 30 kg |
*Total dosage required for full commissioning: Only 30 kg over 25 days.
4. Performance Results & Analytics
Clear water separation was observed at digester ports 3, 4, and 5, showing healthy granular sludge formation and stable biogas production.
Key Metrics Achieved
COD Reduction: The UASBR reduced influent COD from 7,187 mg/L to 874 mg/L, achieving 85 to 90% organic load removal during biological commissioning.
Stable Reactor Performance: A VFA to alkalinity ratio of 0.18 confirmed excellent buffering capacity and stable anaerobic digestion, remaining well below the recommended threshold of 0.30.
Healthy Granular Sludge Formation: Port sample observations showed clear water separation and dense granular sludge development, indicating an active microbial population and sustained biological performance.
Operational Benefits
Zero System Souring: Prevented costly organic overloads and secondary shock treatment expenses.
Improved process reliability: Increased resistance to organic load fluctuations
Rapid Commissioning: Achieved regulatory compliance in under 30 days without trial-and-error chemical additions.
Lower operating costs: Reduced commissioning time, corrective interventions, and operating expenses
Ready to Optimize Your ETP Performance?
Get a customized dosing plan and technical consultation tailored to your plant's specific effluent parameters.
Step 1: Share your inlet COD, BOD, and flow parameters.
Step 2: Our bio-engineers analyze your process flow diagram.
Step 3: Receive a custom BactaServe dosing protocol with performance guidance.
Frequently Asked Questions
Q1: How do you reduce high COD in pharmaceutical wastewater using UASBR?
BactaServe Anaerobic introduced a specialised bacterial consortium designed to speed up hydrolysis, acidogenesis, acetogenesis, and methanogenesis. In a 30 KLD oral cephalosporin API plant, the bio-formulation quickly broke down complex organic pollutants, reducing UASBR inlet COD from 7,187 mg/L to 874 mg/L within 25 days.
Performance Highlights:
Target Effluent: High-strength Active Pharmaceutical Ingredient (API) wastewater containing Cefixime, Cefdinir, and Cefuroxime.
Rapid Commissioning: Full system stabilisation achieved in 25 days using only 30 kg of product.
System Efficiency: Delivered 85 to 90% COD removal across the UASBR stage without chemical shock treatment.
Q2: Why is the VFA/Alkalinity ratio critical for UASBR reactor stability in pharmaceutical ETPs?
The VFA/Alkalinity ratio measures the buffering capacity of a UASBR reactor against organic acid build-up. Keeping the ratio below 0.30 helps prevent digester souring. In this case study, BactaServe Anaerobic maintained an optimal ratio of 0.18 with 514.5 mg/L VFA and 2,821.5 mg/L Alkalinity.
Operational Safety:
Prevents System Souring: Helps stop excessive Volatile Fatty Acids (VFAs) from affecting methanogenic bacteria.
Biogas Optimisation: Supports efficient conversion of acetic acid into methane (CH₄) and carbon dioxide (CO₂).
Reduces Organic Shock Loads: Helps protect downstream aeration tanks and secondary settling tanks from sudden organic load increases.
Q3: How does BactaServe Anaerobic compare to traditional cow dung seed sludge for UASBR start-up?
BactaServe Anaerobic contains a high-density microbial culture developed specifically for complex API wastewater, helping stabilise UASBR reactors within 25 days. Traditional cow dung seed sludge usually requires 60 to 90 days, has lower resistance to shock loads, and carries a higher risk of process failure.
Comparison Summary:
Traditional Seed Sludge: Slow start-up of 2 to 3 months, unstable VFA levels, higher risk of sludge washout, and poor adaptation to toxic API wastewater.
BactaServe Anaerobic: Fast 25-day start-up, better shock-load tolerance, and supports rapid granular sludge formation inside the digester.
Q4: What is the recommended dosing protocol for commissioning a 30 KLD UASBR using BactaServe Anaerobic?
Commissioning a 30 KLD UASBR requires a total of 30 kg of BactaServe Anaerobic over 25 days. The recommended protocol is to dose 5 kg every 5 days on Days 1, 5, 10, 15, 20, and 25.
Dosing Schedule Breakdown:
Days 1 to 5: Initial 5 kg dose to start the hydrolysis and acidogenesis stages.
Days 10 to 15: Additional 5 kg doses to build a dense granular sludge bed.
Days 20 to 25: Final dosing to establish stable methanogenesis and consistent biogas production.
Q5: What four biological mechanisms occur inside a UASBR when treating high-strength API wastewater?
A UASBR treats organic pollutants through four biological stages: Hydrolysis, which breaks API compounds into soluble monomers; Acidogenesis, which converts the monomers into VFAs; Acetogenesis, which converts VFAs into acetic acid, CO₂, and H₂; and Methanogenesis, which converts acetic acid and H₂ into methane biogas.
Process Control: Specialised bacterial strains help maintain a smooth transition between each stage, preventing VFA build-up during the conversion from acidogenesis to methanogenesis.
Q6: What process flow diagram (PFD) configuration was used for this pharmaceutical ETP?
The 30 KLD pharmaceutical ETP treats wastewater through the following process: Collection Tank, Equalisation Tank, Buffer Tank, UASBR, Primary Settling Tank, Aeration Tank, Secondary Settling Tank, Activated Carbon Filter (ACF), Pressure Sand Filter (PSF), Ultrafiltration (UF), and finally clean discharge or water reuse.
Tertiary Integration: Removing most of the organic load in the UASBR stage helps protect downstream Ultrafiltration (UF) membranes and Activated Carbon Filters (ACF) from severe organic fouling.